Progress in bladder cancer monitoring bodes well for Cellmid
Shares in Cellmid (ASX:CDY) surged nearly 8% on Monday after the company announced several important developments, particularly in relation to its midkine diagnostic license agreement with Pacific Edge Biotechnology.
CDY is an early stage company and historical trading activity is not indicative of future share price performances. Investors considering CDY should not base investment decisions on this data alone. It should also be borne in mind that the company is an early stage exploration group with no immediate production profile.
Pacific Edge is a listed diagnostic company based in New Zealand which has been using CDY’s midkine in their CxBladder test for the diagnosis, prognosis and disease management of bladder cancer since 2010.
Over that period CDY has received total revenues of $1.2 million, including the $92,000 in royalties due to be received for the six months to September 30, 2016.
While this has been a significant income driver for CDY, Pacific Edge’s success in 2016 relating to the provision of the CxBladder test for 10.2 million veterans enrolled in the Veteran’s Administration, as well as for military personnel at 150 US Department of Defence facilities will deliver substantial revenue growth in the future.
In addition to this development, Pacific Edge became Approved Provider to Tricare Health Plan networks in the US, which provide health care to 9.4 million beneficiaries of the US Military Health system.
This occurred in October, indicating the associated upside in income will be more apparent in the first half of calendar year 2017. Furthermore, a full year’s contribution from both initiatives in fiscal 2018 should have a positive impact on CDY’s financial performance in that year
Expanded use of CxBladder is an important long-term revenue driver
Further to these developments, CxBladder monitor has been adopted as a replacement for cystoscopy for low-risk patients monitored for recurrence of bladder cancer by the Waitemata District Health Board.
The fact that clinical results of the same test were accepted for publication in the American Journal of Urology this month suggests CDY may be able to increase its market coverage, thereby growing revenues from this product.
Looking specifically at this development, CDY’s chief executive Maria Halasz said, “Monitoring patients with bladder cancer is one of the most significant market opportunities for Pacific Edge as its non-invasive CxBladder represents a clear improvement in patient care”.
Given many patients have up to 24 visits to their urologist over a five-year period with some requiring lifelong monitoring there is the prospect of extensive growth in product usage, particularly given the fact that urologists will favour products offering high-quality performance data.
As more performance data emerges from clinical collaborations, Halasz expects a broadening use of CxBladder tests.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.